Watch ALDX. Know when insiders buy.
One email the day a filing lands. Free.
ALDX
Aldeyra Therapeutics, Inc.
1.48
+0.00 +0.00%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
58
WATCH · shorts 58
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $89.3MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$23.1MNET CASH $54.7M52W 1.24 – 5.76SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$5.9M | −$5.5M | — | -0.09 | −$4.6M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$3.5M | −$3.5M | — | -0.06 | −$5.1M | — | — | May 7 |
| Q4 2025 · Dec 31derived | — | — | — | −$6.7M | −$6.5M | — | -0.10 | −$5.3M | — | — | Feb 27 |
| Q3 2025 · Sep 30 | — | — | — | −$8M | −$7.7M | — | -0.13 | −$7M | — | — | Nov 5 |
| Q2 2025 · Jun 30 | — | — | — | −$10.2M | −$9.8M | — | -0.16 | −$8.6M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$10.4M | −$9.9M | — | -0.17 | −$12.5M | — | — | May 7 |
| Q4 2024 · Dec 31derived | — | — | — | −$16.6M | −$15.8M | — | -0.27 | −$12M | — | — | Feb 27 |
| Q3 2024 · Sep 30 | — | — | — | −$16.1M | −$15.1M | — | -0.25 | −$8M | — | — | Nov 5 |
| Q2 2024 · Jun 30 | — | — | — | −$18M | −$16.8M | — | -0.28 | −$13.2M | — | — | Aug 7 |
| Q1 2024 · Mar 31 | — | — | — | −$9.4M | −$8.1M | — | -0.14 | −$10M | — | — | May 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$6.1M | −$4.8M | — | -0.08 | $500K | $0 | $500K | Feb 28 |
| Q3 2023 · Sep 30 | — | — | — | −$9.6M | −$8.2M | — | -0.14 | −$8M | $0 | −$8M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$35.3M | −$33.8M | — | -0.56 | −$33.3M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$60.1M | −$55.9M | — | -0.94 | −$43.2M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$42.8M | −$37.5M | — | -0.64 | −$30.3M | $0 | −$30.3M | — | — |
| FY2022 · to Dec 31 | — | — | −$62.7M | −$62M | — | -1.06 | −$56.6M | $16K | −$56.7M | — | — |
| FY2021 · to Dec 31 | — | — | −$56.2M | −$57.8M | — | -1.07 | −$42.6M | $8K | −$42.6M | — | — |
| FY2020 · to Dec 31 | — | — | −$36.4M | −$37.6M | — | -1.11 | −$37.5M | — | — | — | — |
Every number comes from Aldeyra Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.